ANAVEX™ PLUS is a promising, potentially novel combination drug for Alzheimer’s disease.  It combines ANAVEX™ 2-73 PLUS donepezil (Aricept®), the best-selling Alzheimer’s drug with annual global sales of $4 billion.

ANAVEX PLUS shows a highly encouraging synergistic effect in Alzheimer’s disease models, producing up to 80% greater reversal of memory loss and neuroprotection when used in combination, versus when the drugs were administered individually.

The drug combination candidate might have a lower clinical trial risk because donepezil (Aricept®) is already FDA approved and on the market.

ANAVEX PLUS also represents a compelling commercial opportunity because donepezil (Aricept®) is now generic. A patent application filed for the combination would, if granted, provide protection until 2033.

Patent application

Anavex has filed a patent application for the ANAVEX PLUS combination of donepezil (Aricept®) and ANAVEX 2-73. If granted, patent protection for ANAVEX PLUS will be in place until at least 2033.